newsfilter
← Latest News
GlobeNewswire·

Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th

  • Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) announced that CEO Laxminarayan Bhat will present at the Life Sciences Investor Forum on June 24, 2026.
  • The presentation is scheduled for 1:30 PM ET as an interactive online event hosted by VirtualInvestorConferences.com.
  • Reviva management will hold one-on-one meetings on June 26 & June 30 upon scheduling via the provided link.
  • A replay of the webcast will be available after the conference concludes.
  • The company is a late-stage biopharmaceutical entity focusing on central nervous system, inflammatory, & cardiometabolic diseases.
  • Reviva's pipeline includes two in-house discovered new chemical entities: brilaroxazine (RP5063) & RP1208.
  • Composition of matter patents for both drug candidates are granted in the United States, Europe, & several other countries.
  • The company plans to initiate the registrational RECOVER-2 Phase 3 trial for brilaroxazine to treat schizophrenia.
  • Reviva intends to use a new form of brilaroxazine in the RECOVER-2 trial & future NDA submissions.
  • The press release includes forward-looking statements regarding clinical development, FDA alignment, & regulatory timelines.
  • Reviva's common stock is transitioning to quotation on the OTCQB Venture Market, which carries risks regarding liquidity & volatility.
  • Corporate contact is Laxminarayan Bhat, PhD, while investor relations inquiries are directed to LifeSci Advisors, LLC.